Aptinyx Inc. got a lot accomplished with its pipeline of small molecule NMDA receptor modulators after it closed a $65m Series A venture capital round in May 2016. So, with several key milestones met, the company revealed on Dec. 18 that it has raised a $70m Series B round to support its new goals.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?